Stock · PPLPHARMA · Healthcare
PPLPHARMA share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for PIRAMAL PHARMA LIMITED, refreshed every end-of-day run. A systematic, data-only read on PIRAMAL PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads PPLPHARMA as constructive with a Crack Score of 82/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where PPLPHARMA stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
0/100Money flow
83/100Result pulse · Q4 FY26
32/100Technical evidence
money-flow score 83.2/100
Chaikin money flow +0.101 (accumulation)
up/down volume 2.88x (buyers dominant)
MFI 76.9
relative strength rising vs NIFTY
RS slope +12.7% (3m)
outperforming and above 50DMA
Valuation and context
no clean TTM P/E (valuation suppressed)
Red flags
above 200DMA (not a confirmed short-side trend)
profit collapse (-105.75% YoY)
strong accumulation tape
weak filed result (score 32.0)
Relative valuation
P/E (TTM)
n/aP/E vs sector
n/aSector percentile
n/aPEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for PPLPHARMA are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the PPLPHARMA chart, refreshed every end-of-day run.
The Crack Score, and how it is built82 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for PPLPHARMA, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on PPLPHARMA reads right now.
The editorial price read on PPLPHARMA is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on PPLPHARMA can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving PPLPHARMA.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why PPLPHARMA moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
PIRAMAL PHARMA LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
32 / 100Revenue
Rs 2,752 crNet profit
Rs -9 crEPS (quarter)
Rs -0.07| Growth | YoY | QoQ |
|---|---|---|
| Revenue | -0.1% | +28.6% |
| Net profit | -105.8% | +93.5% |
| Net margin | -0.3% | |
Figures are the Q4 FY26 result for PIRAMAL PHARMA LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter15 quarters on record
PIRAMAL PHARMA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Sep 2022. These are quarterly facts, not TTM valuation inputs.
PPLPHARMA official result trail
15 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 2,752 cr | Rs 0.07 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 2,140 cr | Rs -1.03 | n/a | 32/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 2,044 cr | Rs 0.75 | n/a | n/a | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 1,934 cr | Rs -0.62 | n/a | 42/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 2,754 cr | Rs 1.16 | n/a | 50/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 2,204 cr | Rs 0.03 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 2,242 cr | Rs 0.17 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 1,951 cr | Rs -0.67 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 2,552 cr | Rs 0.77 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 1,959 cr | Rs 0.08 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 1,911 cr | Rs 0.04 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 1,749 cr | Rs -0.83 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 2,164 cr | Rs 0.42 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 1,716 cr | Rs -0.76 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 1,720 cr | Rs -0.31 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
PIRAMAL PHARMA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
8,869 crNet profit (TTM)
-326 crEBIT (TTM)
108 crProfit before tax (TTM)
-233 crNet margin (TTM)
-3.7%Finance costs (TTM)
341 crBalance sheet, as filed 2026-03-31
Total assets
17,965 crShareholder equity
8,163 crTotal borrowings
5,495 crCash and equivalents
1,200 crInventory
3,064 crTrade receivables
2,158 crThe cash engine, latest filed year
Operating cash flow
1,653 crCapex
890 crFree cash flow
763 crInvesting flow
-826 crFinancing flow
-39.0 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 8,869 cr | -326 cr | 8,163 cr | 5,495 cr | 1,653 cr |
| FY25 | 9,151 cr | 91.1 cr | 8,125 cr | 4,720 cr | 892 cr |
| FY24 | 8,171 cr | 17.8 cr | 7,911 cr | 4,559 cr | 1,005 cr |
| FY23 | 7,082 cr | -186 cr | 6,774 cr | 5,505 cr | 484 cr |
Every figure is parsed from PIRAMAL PHARMA LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record6 earnings calls
Every PPLPHARMA earnings call BazaarBaazi has indexed, latest 31 Oct 2025. Read management in its own words, straight from the filed transcript.
PIRAMAL PHARMA LIMITED earnings calls on record
6 calls since 30 Nov 2022
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed2 disclosures
Every recent official filing from PIRAMAL PHARMA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
PIRAMAL PHARMA LIMITED has filed 2 official disclosures recently. The most recent is a Earnings dated 31 Mar 2026.
Event Heat
50 / 100Event Heat is a dated net read of PIRAMAL PHARMA LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the PPLPHARMA chart. Not a substitute for a registered research note.
| Ticker | PPLPHARMA |
|---|---|
| Full name | PIRAMAL PHARMA LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE0DK501011 |
| Market-cap band | ~23,286 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | PPLPHARMA |
Reference chartLevels in show
The daily frame the desk reads on PPLPHARMA.
FAQ11 reader questions · AEO-eligible
The line on PPLPHARMA, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the PPLPHARMA share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on PPLPHARMA. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for PPLPHARMA?
The BazaarBaazi Crack Score for PPLPHARMA is 82 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on PPLPHARMA?
Strike-level option inventory for PPLPHARMA is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is PPLPHARMA in and which peers does BazaarBaazi track?
PPLPHARMA sits in Healthcare (mid cap), indicative market cap ~23,286 cr (indicative), ISIN INE0DK501011. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on PIRAMAL PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the PPLPHARMA view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on PPLPHARMA is bullish, published in Systematic Read on 21 Jul 2026.
Is PPLPHARMA a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, PIRAMAL PHARMA LIMITED sits in the Scanned tier with a setup score of 65/100 (technical 100, fundamental 0). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read PIRAMAL PHARMA LIMITED's earnings call transcripts?
BazaarBaazi indexes 6 PPLPHARMA earnings calls going back to 2022-11-30, latest 2025-10-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was PIRAMAL PHARMA LIMITED's Q4 FY26 net profit?
PIRAMAL PHARMA LIMITED reported a net profit of Rs -9 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -105.8% year on year. The figure is from the company's official NSE filing.
What was PIRAMAL PHARMA LIMITED's Q4 FY26 revenue?
PIRAMAL PHARMA LIMITED reported revenue of Rs 2,752 cr for Q4 FY26. That is -0.1% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate PIRAMAL PHARMA LIMITED's Q4 FY26 result?
BazaarBaazi gives PIRAMAL PHARMA LIMITED's Q4 FY26 result a Result Pulse of 32 out of 100, with a verdict of Weak. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Piramal Pharma Ltd announced recently?
The most recent official filing on record for Piramal Pharma Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside PPLPHARMA, each a living view refreshed every end-of-day run.